More recently, the Keynote‐811 trial reported that pembrolizumab in combination with trastuzumab and chemotherapy as first‐line therapy significantly improved the efficacy than trastuzumab plus chemotherapy for patients with HER2 overexpression‐positive advanced GC. Here, ERBB2 is linked to gastric cancer.